Global Studies of Using Fecal Biomarkers in Predicting Relapse in Inflammatory Bowel Disease

Frontiers in Medicine

article

Fang Liu¹  Seul A. Lee²  Stephen M. Riordan³  Li Zhang²  Lixin Zhu¹ 

[1] Department of General Surgery and Central Laboratory, The First Affiliated Hospital of Anhui Medical University;School of Biotechnology and Biomolecular Sciences, University of New South Wales;Gastrointestinal and Liver Unit, Prince of Wales Hospital, University of New South Wales

关键词: inflammatory bowel disease;    Crohn's disease;    ulcerative colitis;    fecal biomarkers;    prediction;    calprotectin;    lactoferrin;    S100A12;   

DOI  :  10.3389/fmed.2020.580803

学科分类：社会科学、人文和艺术（综合）

来源: Frontiers

【 摘 要 】

Inflammatory bowel disease (IBD) is a chronic inflammatory condition of the gastrointestinal tract mainly comprising two forms including Crohn's disease (CD) and ulcerative colitis (UC). IBD is a lifelong relapsing remitting disease and relapses occur at random patterns which are unpredictable. Fecal biomarkers have been increasingly used to assess disease activity in IBD due to their positive correlations with intestinal inflammation. Recent studies have also assessed the use of fecal biomarkers in predicting relapse and post-operative recurrence. This review provides information from global studies of using fecal calprotectin, lactoferrin and S100A12 to predict relapse in IBD. Strategies for further studies and the use of these fecal biomarkers for personalized management in IBD are also discussed.

【 授权许可】

CC BY